Forkhead box protein O1 negatively regulates skeletal myocyte differentiation through degradation of mammalian target of rapamycin pathway components.
暂无分享,去创建一个
[1] R. DePinho,et al. A Foxo/Notch pathway controls myogenic differentiation and fiber type specification. , 2007, The Journal of clinical investigation.
[2] M. Febbraio,et al. FOXO1 Regulates the Expression of 4E-BP1 and Inhibits mTOR Signaling in Mammalian Skeletal Muscle* , 2007, Journal of Biological Chemistry.
[3] N. Mochizuki,et al. Interaction of FoxO1 and TSC2 Induces Insulin Resistance through Activation of the Mammalian Target of Rapamycin/p70 S6K Pathway* , 2006, Journal of Biological Chemistry.
[4] Daniel J. Hoeppner,et al. Notch signalling regulates stem cell numbers in vitro and in vivo , 2006, Nature.
[5] K. Ikeda,et al. A novel ubiquitin‐binding protein ZNF216 functioning in muscle atrophy , 2006, The EMBO journal.
[6] In-Hyun Park,et al. Mammalian Target of Rapamycin (mTOR) Signaling Is Required for a Late-stage Fusion Process during Skeletal Myotube Maturation*[boxs] , 2005, Journal of Biological Chemistry.
[7] T. Rando,et al. The regulation of Notch signaling in muscle stem cell activation and postnatal myogenesis. , 2005, Seminars in cell & developmental biology.
[8] T. Unterman,et al. FoxO proteins in insulin action and metabolism , 2005, Trends in Endocrinology & Metabolism.
[9] Joseph Avruch,et al. Rheb Binds and Regulates the mTOR Kinase , 2005, Current Biology.
[10] K. Esser,et al. FoxO1 Stimulates Fatty Acid Uptake and Oxidation in Muscle Cells through CD36-dependent and -independent Mechanisms* , 2005, Journal of Biological Chemistry.
[11] N. Sonenberg,et al. Upstream and downstream of mTOR. , 2004, Genes & development.
[12] Di Chen,et al. The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span , 2004, Development.
[13] D. Accili,et al. FoxOs at the Crossroads of Cellular Metabolism, Differentiation, and Transformation , 2004, Cell.
[14] G. Yancopoulos,et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. , 2004, Molecular cell.
[15] Marco Sandri,et al. Foxo Transcription Factors Induce the Atrophy-Related Ubiquitin Ligase Atrogin-1 and Cause Skeletal Muscle Atrophy , 2004, Cell.
[16] Michael Majeski,et al. Multiple elements regulate nuclear/cytoplasmic shuttling of FOXO1: characterization of phosphorylation- and 14-3-3-dependent and -independent mechanisms. , 2004, The Biochemical journal.
[17] In-Hyun Park,et al. IGF-II transcription in skeletal myogenesis is controlled by mTOR and nutrients , 2003, The Journal of cell biology.
[18] Hitomi Matsuzaki,et al. Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[19] D. Accili,et al. Regulation of insulin-like growth factor–dependent myoblast differentiation by Foxo forkhead transcription factors , 2003, The Journal of cell biology.
[20] J. Lawrence,et al. Two Motifs in the Translational Repressor PHAS-I Required for Efficient Phosphorylation by Mammalian Target of Rapamycin and for Recognition by Raptor* , 2003, Journal of Biological Chemistry.
[21] J. Blenis,et al. TOS Motif-Mediated Raptor Binding Regulates 4E-BP1 Multisite Phosphorylation and Function , 2003, Current Biology.
[22] J. Avruch,et al. The Mammalian Target of Rapamycin (mTOR) Partner, Raptor, Binds the mTOR Substrates p70 S6 Kinase and 4E-BP1 through Their TOR Signaling (TOS) Motif* , 2003, The Journal of Biological Chemistry.
[23] Eric C. Griffith,et al. The Many Forks in FOXO's Road , 2003, Science's STKE.
[24] G. Grosveld,et al. FKHR (FOXO1a) is required for myotube fusion of primary mouse myoblasts , 2003, The EMBO journal.
[25] O. Hino,et al. Tsc tumour suppressor proteins antagonize amino-acid–TOR signalling , 2002, Nature Cell Biology.
[26] D. Sabatini,et al. mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery , 2002, Cell.
[27] J. Avruch,et al. Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR Action , 2002, Cell.
[28] P. Houghton,et al. Myogenic Differentiation Is Dependent on Both the Kinase Function and the N-terminal Sequence of Mammalian Target of Rapamycin* , 2002, The Journal of Biological Chemistry.
[29] F. Barr,et al. Molecular Pathogenesis of Rhabdomyosarcoma , 2002, Cancer biology & therapy.
[30] C. R. Kaffer,et al. Regulatory Mechanisms at the MouseIgf2/H19 Locus , 2001, Molecular and Cellular Biology.
[31] Jie Chen,et al. The Mammalian Target of Rapamycin Regulates C2C12 Myogenesis via a Kinase-independent Mechanism* , 2001, The Journal of Biological Chemistry.
[32] Antonio Musarò,et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle , 2001, Nature Genetics.
[33] M. Benito,et al. Insulin produces myogenesis in C2C12 myoblasts by induction of NF‐κB and downregulation of AP‐1 activities , 2001, Journal of cellular physiology.
[34] E. Olson,et al. MEF2: a transcriptional target for signaling pathways controlling skeletal muscle growth and differentiation. , 1999, Current opinion in cell biology.
[35] A. Musarò,et al. Maturation of the Myogenic Program Is Induced by Postmitotic Expression of Insulin-Like Growth Factor I , 1999, Molecular and Cellular Biology.
[36] P. Vogt,et al. Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[37] P. Cohen,et al. Stress-activated Protein Kinase-2/p38 and a Rapamycin-sensitive Pathway Are Required for C2C12 Myogenesis* , 1999, The Journal of Biological Chemistry.
[38] A. Musarò,et al. Viral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[39] P. Vogt,et al. An essential role of phosphatidylinositol 3-kinase in myogenic differentiation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[40] M. Palacín,et al. Phosphatidylinositol 3-Kinase Inhibitors Block Differentiation of Skeletal Muscle Cells* , 1996, The Journal of Biological Chemistry.
[41] Harold Weintraub,et al. The MyoD family and myogenesis: Redundancy, networks, and thresholds , 1993, Cell.
[42] G. Crabtree,et al. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases , 1992, Cell.
[43] J R Florini,et al. "Spontaneous" differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin-like growth factor-II. , 1991, The Journal of biological chemistry.
[44] P. Rotwein,et al. Insulin-like growth factors (IGF) in muscle development. Expression of IGF-I, the IGF-I receptor, and an IGF binding protein during myoblast differentiation. , 1989, The Journal of biological chemistry.
[45] P. Rotwein,et al. Coordinate expression of insulin-like growth factor II and its receptor during muscle differentiation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[46] M. Palacín,et al. Insulin-like growth factors require phosphatidylinositol 3-kinase to signal myogenesis: dominant negative p85 expression blocks differentiation of L6E9 muscle cells. , 1998, Molecular endocrinology.
[47] J. Florini,et al. Hormones, growth factors, and myogenic differentiation. , 1991, Annual review of physiology.